Yanet Climent
0000-0002-2824-6374
2 papers found
Refreshing results…
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
Missing publications? Search for publications with a matching author name.